Mitchell David Nambu

USPTO Granted Patents = 11 (Patent Applications = 4)

CIPO Patents = 4

EPO Patents = 9 (Patent Applications = 1)

Average Co-Inventor Count = 10.4

ph-index = 8

Forward Citations = 232(Granted Patents)

Company Filing History:

Agouron Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2003-2014

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8785632 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2014-07-22),

2. 8633204 - 4-methylpyridopyrimidinone compounds (2014-01-21),

3. 8273755 - 4-methylpyridopyrimidinone compounds (2012-09-25),

4. 8106197 - Aminoheteroaryl compounds as protein kinase inhibitors (2012-01-31),

5. 7868026 - Therapeutic compounds (2011-01-11),

6. 7858643 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2010-12-28),

7. 7732604 - Triazolopyrazine derivatives (2010-06-08),

8. 7696213 - 4-methylpyridopyrimidinone compounds (2010-04-13),

9. 7230098 - Aminoheteroaryl compounds as protein kinase inhibitors (2007-06-12),

10. 6635641 - Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use (2003-10-21),

11. 6620828 - Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use (2003-09-16),

Title: The Innovative Contributions of Mitchell David Nambu

Introduction

Mitchell David Nambu, based in San Diego, CA, is a notable inventor with a remarkable portfolio of 11 patents. His work primarily focuses on developing novel compounds that target critical pathways in disease mechanisms, particularly in the realm of cancer research.

Latest Patents

Among his latest innovations, Nambu has developed enantiomerically pure aminoheteroaryl compounds which act as protein kinase inhibitors. These compounds, characterized by their formula, are significant due to their potency against the c-Met protein kinase and their potential applicability in treating cancers and other disorders related to abnormal cell growth. Another significant invention is the 4-methylpyridopyrimidinone compounds. These novel compounds and their derivatives are designed to inhibit phosphoinositide 3-kinase alpha (PI3-Kα), contributing to a deeper understanding of cancer biology and therapeutic intervention.

Career Highlights

Nambu's career includes tenure at esteemed pharmaceutical giants such as Pfizer Corporation and Agouron Pharmaceuticals, Inc. His contributions in these companies have been critical to advancing therapeutics aimed at various health issues, particularly in oncology.

Collaborations

Throughout his career, Nambu has collaborated with notable individuals, including Mason Alan Pairish and Dilip Ramakant Bhumralkar. These partnerships have fostered significant advancements in his research, resulting in impactful innovations in the pharmaceutical and biotechnology fields.

Conclusion

Mitchell David Nambu's dedication to innovation is reflected in his extensive patent portfolio and his impactful collaborations. His work not only contributes to scientific knowledge but also holds promise for developing effective treatments for cancer and other serious health conditions.

This text is generated by artificial intelligence and may not be accurate.